Literature DB >> 29937

Demonstration of opsonic activity and in vivo protection against group B streptococci type III by Streptococcus pneumoniae type 14 antisera.

G W Fischer, G H Lowell, M H Crumrine, J W Bass.   

Abstract

The present studies demonstrate that antisera directed against Streptococcus pneumoniae type 14 is opsonic for group B streptococci type III in a neutrophile-mediated bactericidal assay. Specificity was demonstrated by the observations that group B streptococci type III and S. pneumoniae type 14 adsorbed the opsonic activity of anti-S. pneumoniae type 14 antisera. Group B streptococci strain 090R (devoid of type antigens) and S. pneumoniae type 3, did not remove the opsonic activity of anti-S. pneumoniae type 14 serum. In vivo studies using a suckling rat model of neonatal group B streptococcal type III sepsis demonstrated that antisera directed against S. pneumoniae type 14 was highly protective.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 29937      PMCID： PMC2185002          DOI： 10.1084/jem.148.3.776

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


  22 in total

1.  Group B streptococcus in a general hospital.

Authors:  B F Anthony; N F Concepcion
Journal:  J Infect Dis       Date:  1975-11       Impact factor: 5.226

2.  STUDIES ON HEAT-LABILE OPSONIN IN RABBIT SERUM.

Authors:  J G HIRSCH; B STRAUSS
Journal:  J Immunol       Date:  1964-01       Impact factor: 5.422

3.  NEONATAL SEPSIS AND OTHER INFECTIONS DUE TO GROUP B BETA-HEMOLYTIC STREPTOCOCCI.

Authors:  T C EICKHOFF; J O KLEIN; A K DALY; D INGALL; M FINLAND
Journal:  N Engl J Med       Date:  1964-12-10       Impact factor: 91.245

4.  Beta hemolytic streptococcus group B associated with problems of the perinatal period.

Authors:  M HOOD; A JANNEY; G DAMERON
Journal:  Am J Obstet Gynecol       Date:  1961-10       Impact factor: 8.661

5.  Structural studies on the specific type-14 pneumococcal polysaccharide.

Authors:  B Lindberg; J Lönngren; D A Powell
Journal:  Carbohydr Res       Date:  1977-09       Impact factor: 2.104

6.  The isolation and some physiochemical and biologic properties of the type 3 antigen of group B streptococci.

Authors:  H Russell; N L Norcross
Journal:  J Immunol       Date:  1972-07       Impact factor: 5.422

Review 7.  Pneumococcal bacteremia. Review of 111 cases, 1957--1969, with special reference to cases with undetermined focus.

Authors:  J P Burke; J O Klein; H M Gezon; M Finland
Journal:  Am J Dis Child       Date:  1971-04

8.  Neonatal infections caused by group B streptococci.

Authors:  G Bergqvist; B Hurvell; A S Malmborg; M Rylander; R Tunell
Journal:  Scand J Infect Dis       Date:  1971

9.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

10.  Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens.

Authors:  R C Lancefield; M McCarty; W N Everly
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307
View more
  23 in total

Review 1.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

2.  Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide.

Authors:  B J Stoll; M Pollack; L S Young; N Koles; R Gascon; G B Pier
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

3.  Group B streptococcal infection in the newborn.

Authors:  M I Marks
Journal:  Can Med Assoc J       Date:  1979-10-20       Impact factor: 8.262

4.  Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid.

Authors:  T Lagergard; J Shiloach; J B Robbins; R Schneerson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

5.  The mode of action of antibody in neutrophil bactericidal activity against highly pathogenic group-B streptococci.

Authors:  P H Cleat; C R Coid
Journal:  Med Microbiol Immunol       Date:  1984       Impact factor: 3.402

6.  An alternative role for specific antibody in neutrophil bactericidal activity against highly pathogenic group B streptococci.

Authors:  P H Cleat; C R Coid
Journal:  Br J Exp Pathol       Date:  1982-08

7.  Use of monoclonal antibodies in an enzyme immunoassay for rapid identification of group B Streptococcus types II and III.

Authors:  R A Polin; R Kennett
Journal:  J Clin Microbiol       Date:  1980-04       Impact factor: 5.948

8.  Enzyme-linked immunosorbent assay for group B streptococcal antibodies.

Authors:  N S Rote; N L Taylor; A O Shigeoka; J R Scott; H R Hill
Journal:  Infect Immun       Date:  1980-01       Impact factor: 3.441

9.  Functional characteristics of a modified immunoglobulin preparation for intravenous administration: summary of studies of opsonic and protective activity against group B streptococci.

Authors:  G W Fischer; S R Wilson; K W Hunter
Journal:  J Clin Immunol       Date:  1982-04       Impact factor: 8.317

10.  The interleukin-1 receptor antagonist can either reduce or enhance the lethality of Klebsiella pneumoniae sepsis in newborn rats.

Authors:  J Mancilla; P García; C A Dinarello
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.